A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances

Mark Weiser, Heschi H. Rotmensch, Amos D. Korczyn, Richard Hartman, Ana Cicin-Sain, Ravi Anand

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The majority of patients with Alzheimer's disease (AD) or vascular dementia display, in addition to cognitive impairment, various degrees of behavioral disturbances. As the use of cholinesterase inhibitors for the treatment of cognitive impairment in dementia becomes widespread, many of these patients will be treated concomitantly with cholinesterase inhibitors and with anti-psychotic drugs to ameliorate behavioral disturbances. Despite the widespread use of this combination in clinical practice, the safety and tolerability of such combination therapy has not been evaluated in controlled clinical trials. This pilot study examined the effects of addition of risperidone 0.5-2 mg/day to patients on rivastigmine 3-12 mg/day, and vice versa. Methods: 65 patients suffering from AD, 10 from vascular dementia, and 15 from both were randomized to open label rivastigmine and risperidone, alone or in combination, for 20 weeks. Adverse events caused by co-administration were assessed. Results: No clinically relevant adverse interactions were observed. Conclusions: These preliminary results indicate that rivastigmine and risperidone can be safely co-administered. Confirmation of these results in large clinical trials studies is warranted.

Original languageEnglish
Pages (from-to)343-346
Number of pages4
JournalInternational Journal of Geriatric Psychiatry
Volume17
Issue number4
DOIs
StatePublished - 2002
Externally publishedYes

Keywords

  • Behavioral disturbances
  • Dementia
  • Risperidone
  • Rivastigmine

Fingerprint

Dive into the research topics of 'A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances'. Together they form a unique fingerprint.

Cite this